Compare Comcast Corporation (CMCSA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Sanofi SA — how do they compare? Comcast Corporation trades at $25.29 (market cap $91.02B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Comcast Corporation and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| CMCSA | SNY | |
|---|---|---|
Market Cap | $91.02B | $104.30B |
Sector | Media | Health |
52-Week High | $32.50 | $52.34 |
52-Week Low | $21.92 | $41.33 |
Enterprise Value | $173.74B | $124.19B |
Dividend Yield | 5.15% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CMCSA trades at $25.185, down slightly by 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The company shows strong fundamentals with a low P/E of 8.22, consistent earnings beats in recent quarters, and robust cash flow generation of $33.64 billion from operations in 2025. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff.
The outlook for CMCSA is positive, supported by attractive valuation, steady dividend payments, and growth in wireless and streaming. Key risks include competitive pressures in media and broadband, execution of the spinoff, and macroeconomic sensitivity. Analyst consensus is bullish with a $27.78 price target, implying potential upside from current levels.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
